Hereditary Spastic Paraplegia in Koreans: Clinical Characteristics and Factors Influencing the Disease Severity
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Hereditary spastic paraplegia (HSP) progresses over time and is associated with locomotive dysfunction. Understanding the factors affecting disease severity and locomotive function is important in HSP. This study investigated the factors influencing disease severity and ambulation status of HSP. Methods We consecutively enrolled 109 Korean patients (64 males, and 45 females)from 84 families with a clinical diagnosis of HSP. HSP was primarily diagnosed based on clinical criteria including clinical findings, family history, and supported by genetic studies. Epidemiological and clinical features of the patients were analyzed, and the Spastic Paraplegia Rating Scale (SPRS) score and ambulatory status were used to evaluate disease severity. Results Ninety-two (84.4%) patients had pure HSP, and 55 (50.4%) had a dominant family history. Thirty-one (28.4%) patients required a mobility aid for locomotion. A Kaplan-Meier analysis showed that HSP patients lost their independent gait ability after a median disease duration of 34 years. Those with an age at onset of ≤18 years had a longer median independent walking time. Pure HSP is characterized by predominant bilateral lower extremity weakness and spasticity, whereas complicated HSP presents more complex neurological findings such as ocular and bulbar symptoms, ataxia, and cognitive impairment. Complicated HSP was significantly correlated with the SPRS mobility score (β=3.70, 95% confidence interval=0.45–6.94). The age at onset and disease duration were significantly correlated with disease severity, and they were significant predictors of the use of a mobility aid (p<0.05). Conclusions These findings suggest that a later age at onset and longer disease duration are significant factors affecting the disease severity and ambulatory function in patients with HSP. These findings can help clinicians to identify subjects at risk of locomotive impairment.
Abstract
Background and Purpose Hereditary spastic paraplegia (HSP) progresses over time and is associated with locomotive dysfunction. Understanding the factors affecting disease severity and locomotive function is important in HSP. This study investigated the factors influencing disease severity and ambulation status of HSP. Methods We consecutively enrolled 109 Korean patients (64 males, and 45 females)from 84 families with a clinical diagnosis of HSP. HSP was primarily diagnosed based on clinical criteria including clinical findings, family history, and supported by genetic studies. Epidemiological and clinical features of the patients were analyzed, and the Spastic Paraplegia Rating Scale (SPRS) score and ambulatory status were used to evaluate disease severity. Results Ninety-two (84.4%) patients had pure HSP, and 55 (50.4%) had a dominant family history. Thirty-one (28.4%) patients required a mobility aid for locomotion. A Kaplan-Meier analysis showed that HSP patients lost their independent gait ability after a median disease duration of 34 years. Those with an age at onset of ≤18 years had a longer median independent walking time. Pure HSP is characterized by predominant bilateral lower extremity weakness and spasticity, whereas complicated HSP presents more complex neurological findings such as ocular and bulbar symptoms, ataxia, and cognitive impairment. Complicated HSP was significantly correlated with the SPRS mobility score (β=3.70, 95% confidence interval=0.45–6.94). The age at onset and disease duration were significantly correlated with disease severity, and they were significant predictors of the use of a mobility aid (p<0.05). Conclusions These findings suggest that a later age at onset and longer disease duration are significant factors affecting the disease severity and ambulatory function in patients with HSP. These findings can help clinicians to identify subjects at risk of locomotive impairment.
참고문헌 (28)
- Salinas S, "Hereditary spastic paraplegia : clinical features and pathogenetic mechanisms", Lancet Neurol, 7, pp.1127~1138 (2008)
- Ishiura H, "Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses", J Hum Genet, 59, pp.163~172 (2014)
- Schüle R, "Genetics of hereditary spastic paraplegias", Semin Neurol, 31, pp.484~493 (2011)
- Shribman S, "Hereditary spastic paraplegia : from diagnosis to emerging therapeutic approaches", Lancet Neurol, 18, pp.1136~1146 (2019)
- Fink JK, "Hereditary spastic paraplegia : clinico-pathologic features and emerging molecular mechanisms", Acta Neuropathol, 126, pp.307~328 (2013)
- Agosta F, "Hereditary spastic paraplegia : beyond clinical phenotypes toward a unified pattern of central nervous system damage", Radiology, 276, pp.207~218 (2015)
- Finsterer J, "Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance", J Neurol Sci, 318, pp.1~18 (2012)
- Erfanian Omidvar M, "Genotype-phenotype associations in hereditary spastic paraplegia : a systematic review and meta-analysis on 13, 570patients", J Neurol, 268, pp.2065~2082 (2021)
- Noreau A, "Molecular aspects of hereditary spastic paraplegia", Exp Cell Res, 325, pp.18~26 (2014)
- Lo Giudice T, "Hereditary spastic paraplegia : clinical-genetic characteristics and evolving molecular mechanisms", Exp Neurol, 261, pp.518~539 (2014)
- Klimpe S, "Disease severity affects quality of life of hereditary spastic paraplegia patients", Eur J Neurol, 19, pp.168~171 (2012)
- Schüle R, "Hereditary spastic paraplegia : clinicogenetic lessons from 608 patients", Ann Neurol, 79, pp.646~658 (2016)
- Schüle R, "The spastic paraplegia rating scale(SPRS) : a reliable and valid measure of disease severity", Neurology, 67, pp.430~434 (2006)
- Harding AE, "Classification of the hereditary ataxias and paraplegias", Lancet, 1, pp.1151~1155 (1983)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Fink JK, "Sporadically occurring neurologic disease : HSP genes and apparently sporadic spastic paraplegia", Neurology, 71, pp.1468~1469 (2008)
- Adry RA, "Comparison between the spastic paraplegia rating scale, Kurtzke scale, and Osame scale in the tropical spastic paraparesis", myelopathy associated with HTLV, 2012, pp.45, 309~312
- Loureiro JL, "Autosomal dominant spastic paraplegias : a review of 89 families resulting from a portuguese survey", JAMA Neurol, 70, pp.481~487 (2013)
- Chrestian N, "Clinical and genetic study of hereditary spastic paraplegia in Canada", Neurol Genet, 3, pp.e122~ (2017)
- Lin JZ, "Cortical damage associated with cognitive and motor impairment in hereditary spastic paraplegia : evidence of a novel SPAST mutation", Front Neurol, 11, pp.399~ (2020)
- Zhang Y, "The effect of hydrotherapy treatment on gait characteristics of hereditary spastic paraparesis patients", Gait Posture, 39, pp.1074~1079 (2014)
- Heetla HW, "Improved gait performance in a patient with hereditary spastic paraplegia after a continuous intrathecal baclofen test infusion and subsequent pump implantation : a case report", Arch Phys Med Rehabil, 96, pp.1166~1169 (2015)
- Bertolucci F, "Robotic gait training improves motor skills and quality of life in hereditary spastic paraplegia", NeuroRehabilitation, 36, pp.93~99 (2015)
- Braschinsky M, "Functional assessment of lower extremities in hereditary spastic paraplegia", Arch Phys Med Rehabil, 90, pp.1887~1890 (2009)
- Marsden J, "Muscle paresis and passive stiffness : key determinants in limiting function in hereditary and sporadic spastic paraparesis", Gait Posture, 35, pp.266~271 (2012)
- Martinuzzi A, "Clinical and paraclinical indicators of motor system impairment in hereditary spastic paraplegia : a pilot study", PLoS One, 11, pp.e0153283~ (2016)
- Trummer B, "Clinical trial designs and measures in hereditary spastic paraplegias", Front Neurol, 9, pp.1017~ (2018)
- Burguez D, "Clinical and molecular characterization of hereditary spastic paraplegias : a next-generation sequencing panel approach", J Neurol Sci, 383, pp.18~25 (2017)